SPC379

Pegcetacoplan

  • Status:
    Veitt
  • Application date:
    30.5.2022
  • Application published:
    15.7.2022
  • Grant published:
    15.2.2024
  • Max expiry date:
    13.12.2036
  • Medicine name:
    ASPAVELI
  • Medicine for children:
    No

Timeline

Today
30.5.2022Application
15.7.2022Publication
15.2.2024Registration
13.12.2036Expires

Marketing license

  • IS authorization number:
    EU/1/21/1595/001-002
  • Date:
    30.12.2021
  • Foreign authorization number:
    EU/1/21/1595
  • Date:
    13.12.2021

Owner

  • Name:
    Apellis Pharmaceuticals, Inc.
  • Address:
    100 5th Avenue, Waltham US

Agent

  • Name:
    Tego IP ehf.
  • Address:
    Pósthólf 8129, 128 Reykjavík

Patent

Upload documents